

PRINTER RUSH
(PTO ASSISTANCE)

Application : 09/615285 Examiner : Nickol GAU : 1642
From : he Location : (IDC) FMF FDC Date : 9/20/05
Tracking # : 01608 3864 Week Date : 3/14/05

| DOC CODE | DOC DATE | MISCELLANEOUS |
|------------------------------------------|----------|----------------------------------------------|
| <input type="checkbox"/> 1449 | _____ | <input type="checkbox"/> Continuing Data |
| <input type="checkbox"/> IDS | _____ | <input type="checkbox"/> Foreign Priority |
| <input type="checkbox"/> CLM | _____ | <input type="checkbox"/> Document Legibility |
| <input type="checkbox"/> IIFW | _____ | <input type="checkbox"/> Fees |
| <input type="checkbox"/> SRFW | _____ | <input type="checkbox"/> Other |
| <input type="checkbox"/> DRW | _____ | |
| <input type="checkbox"/> OATH | _____ | |
| <input type="checkbox"/> 312 | _____ | |
| <input checked="" type="checkbox"/> SPEC | _____ | |

[RUSH] MESSAGE: Paragraph of text under tables on page 106 refer to bolding. Is the bolding supposed to be in the tables? If so, could you please indicate where because you can't tell.

Thank you.

[XRUSH] RESPONSE: Attorney advised as to which entries were boldface. Attached is a marked-up copy of the page. "B —" is handwritten under items to be printed in boldface. No clearer copy of the original page is available.

INITIALS: def

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04

TABLES

Table 1. Immunohistochemical staining of human tissues with anti-TMPRSS2 monoclonal antibody.

| Staining Intensity | Tissue | Predominant Staining Localization | |
|--------------------|-----------------------|-----------------------------------|---------------------------|
| | | Cytoplasmic | Luminal surface/secretion |
| 5 | | | |
| 10 | None | | |
| | Kidney | | |
| | Skin | | |
| | Lung | | |
| | Liver | | |
| | Testis | | |
| | Spleen | | |
| 15 | Light | | |
| | Fallopian tubes | + | |
| | Colon cancer (1/4) | + | + |
| 20 | Moderate to strong | | |
| | Prostate (7/7) | + | + |
| | BPH (7/7) | + | + |
| | PIN (1/1) | + | + |
| | Colon (4/4) | + | |
| | Pancreas (4/4) | + | |
| 25 | Prostate cancer (5/5) | + | + |
| | Colon cancer (3/3) | + | + |

Table 2: Epitope mapping of anti-TMPRSS2 mAbs

| test mAb | none | competitor mAb | | | | | | |
|----------|-------|----------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| | | 1F9 | 2D10 | 2F8 | 3G3 | 6B11 | 8C6 | 9G8 |
| 30 | 1F9-B | 2.371±0.012 | 0.269±0.001 | 0.730±0.004 | 2.230±0.037 | 0.359±0.005 | 0.353±0.008 | 2.625±0.033 |
| | 2F8-B | 1.390±0.015 | 1.258±0.020 | 1.169±0.005 | 0.407±0.032 | 1.250±0.009 | 1.242±0.020 | 0.371±0.005 |
| 35 | 8C6-B | 1.512±0.004 | 1.899±0.013 | 1.434±0.031 | 1.216±0.062 | 1.803±0.044 | 1.806±0.056 | 0.161±0.005 |
| | | | | | | | | 1.473±0.014 |

A decrease in signal intensity of the biotinylated antibody in the presence of an excess of unlabelled antibody indicates that the mAbs compete for the same or overlapping binding sites (shown in bold). As indicated in Table 2 a decrease in signal intensity of biotinylated 1F9 (1F9-B) is seen in the presence of mAbs 2D10, 3G3, and 6B11, and itself, but not by 2F8, 8C6, and 9G8. These results indicate that mAbs 1F9, 2D10, 3G3, 6B11 share the same (or overlapping) epitope that is distinct from those of 2F8, 8C6, and 9G8. MAb 2F8-B is competed by itself and by mAbs 8C6 and 9G8 indicating these mAbs share the same or overlapping epitopes. MAb 8C6-B is competed by itself and moderately by mAb 2F8. Taken together, these results indicate that the panel of anti-TMPRSS2 antibodies recognize different epitopes within the protease domain of TMPRSS2.